Skip to main content
Terug
Watch Compare

Context Therapeutics Inc.

Datakwaliteit: 83%
CNTX
Nasdaq Manufacturing Chemicals
€ 2,49
▼ € 0,10 (-3,86%)
Marktkapitalisatie: 240,72 M
Prijs
€ 2,62
Marktkapitalisatie
240,72 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -26,42 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-46,40%
Boven sectorgemiddelde (-53,47%)
ROIC-40,27%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio13,10
Interest CoverageN/A

Waardering

PE (TTM)
-6,66
Onder sectorgemiddelde (-1,48)
P/B Ratio3,29
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -6,7 -1,5
P/B 3,3 1,6
ROE % -46,4 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

8 analisten
Buy
Huidig
€ 2,49
+141.0%
Koersdoel
€ 6,00
€ 4,00
€ 5,50
€ 9,00
Vooruitzicht
Forward K/W -5,38
Forward WPA -€ 0,46
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,46
-€ 0,65 – -€ 0,25
 0,0 8
FY2026 -€ 0,47
-€ 0,62 – -€ 0,21
 0,0 9

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,11 -€ 0,14 -32,6%
Q32025 -€ 0,09 -€ 0,10 -14,3%
Q22025 -€ 0,05 -€ 0,09 -73,1%
Q12025 -€ 0,06 -€ 0,05 +21,1%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -36,12 M
ROE -46,40% ROA -43,42%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -26,42 M
ROIC -40,27% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 13,10
Interest Coverage N/A Asset Turnover N/A
Working Capital 73,02 M Tangible Book Value 73,17 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6,66 Forward P/E N/A
P/B Ratio 3,29 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -10,97%
Market Cap 240,72 M Enterprise Value 163,79 M
Per Share
EPS (Diluted TTM) -0,38 Revenue / Share N/A
FCF / Share -0,29 OCF / Share -0,29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 73,14%
SBC-Adj. FCF -27,64 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -36,12 M -26,73 M -23,96 M -14,84 M -10,46 M
EPS (Diluted) -0,38 -0,46 -1,50 -0,93 -3,69
Gross Profit — — — — —
Operating Income -39,70 M -29,92 M -25,07 M -15,38 M -10,53 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A 16.251,0 10.881,0 12.044,0 9.268,0 —
Interest Expense — — 1,16 M 547.268,0 64.240,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 68,49 M 98,13 M 16,06 M 37,97 M 51,31 M
Total Liabilities 8,02 M 2,86 M 4,19 M 3,21 M 3,03 M
Shareholders' Equity 60,47 M 95,27 M 11,87 M 34,76 M 48,27 M
Total Debt — — — — —
Cash & Equivalents 66,00 M 94,43 M 14,45 M 35,50 M 49,64 M
Current Assets 68,35 M 97,90 M 16,05 M 37,85 M 51,26 M
Current Liabilities 8,02 M 2,75 M 4,19 M 3,21 M 3,03 M